Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad spectrum of genetically driven conditions. However, their clinical advancement is significantly hindered by the lack of efficient and specific delivery strategies. Recent progress in conjugate-based delivery systems offers potential solutions for improving the safety and targeted delivery of oligonucleotides to various tissues and organs.

At TIDES Asia 2026, WuXi Biology presented a poster describing the establishment of an integrated service platform to accelerate the discovery of oligonucleotide drugs. The authors highlight case studies with data showing the uptake/efficacy of lipid-conjugated siRNAs, as well as the evaluation of mRNA display–based peptide discovery and the uptake/efficacy of peptide-oligonucleotide conjugates.